Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)

被引：0

作者：

van Meerten, Tom ^{[1
]}

Kersten, M. J. ^{[2
]}

Lacoboni, Gloria ^{[3
]}

Hess, Georg ^{[4
]}

Mutsaers, Pim ^{[5
]}

Garcia-Sancho, Alejandro Martin ^{[6
]}

Goy, Andre ^{[7
]}

Gine, Eva ^{[8
]}

Hill, Brian T. ^{[9
]}

Weng, Wen-Kai ^{[10
]}

Dreyling, Martin ^{[11
]}

Reagan, Patrick M. ^{[12
]}

Patel, Krish ^{[13
]}

Galal, Ahmed ^{[14
]}

Herbaux, Charles ^{[15
]}

Sanderson, Robin ^{[16
]}

Zheng, Dan ^{[17
]}

Kanska, Justyna ^{[17
]}

Zhang, Wangshu ^{[17
]}

Khalid, Rita Damico ^{[17
]}

Kloos, Loana ^{[17
]}

Wang, Michael ^{[18
]}

机构：

[1] Univ Groningen, Univ Med Ctr Groningen, Dept Hematol, Groningen, Netherlands

[2] Locat Univ Amsterdam, Canc Ctr Amsterdam, Amsterdam UMC, Amsterdam, Netherlands

[3] Vall dHebron Univ Hosp, Barcelona, Spain

[4] Johannes Gutenberg Univ Mainz, Mainz, Germany

[5] Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands

[6] Salamanca Univ Hosp, Hematol Dept, IBSAL, CIBERONC, Salamanca, Spain

[7] John Theurer Canc Ctr, Hackensack, NJ USA

[8] Hosp Clin Barcelona, IDIBAPS, CIBERONC, Barcelona, Spain

[9] Cleveland Clin Fdn, Cleveland, OH USA

[10] Stanford Univ, Div Blood & Marrow Transplantat & Cellular Therapy, Sch Med, Palo Alto, CA USA

[11] Ludwig Maximilian Univ Hosp, Dept Med 3, Munich, Germany

[12] Univ Rochester, Med Ctr, Rochester, NY USA

[13] Swedish Canc Inst, Seattle, WA USA

[14] Carol G Simon Canc Ctr, Morristown, NJ USA

[15] CHU Montpellier, Hematol Clin, Montpellier, France

[16] Kings Coll Hosp London, London, England

[17] Kite Gilead Co, Santa Monica, CA USA

[18] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-198021

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：748 / 750

页数：3

共 36 条

[21] Impact of age, prior therapies, and subsequent transplant on long-term outcomes of adults with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.
Shah, Bijal D.
Cassaday, Ryan Daniel
Park, Jae H.
Houot, Roch
Oluwole, Olalekan O.
Logan, Aaron
Boissel, Nicolas
Leguay, Thibaut
Bishop, Michael Russell
Topp, Max S.
O'Dwyer, Kristen M.
Baer, Maria R.
Schiller, Gary J.
Abedi, Mehrdad
Minnema, Monique C.
Stiff, Patrick J.
Zhou, Lang
Hadjivassileva, Tsveta
Khalid, Rita Damico
Ghobadi, Armin
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[22] Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy
Phillips, Tycel
Dickinson, Michael
Morschhauser, Franck
Bachy, Emmanuel
Crump, Michael
Trneny, Marek
Bartlett, Nancy L.
Zaucha, Jan
Humphrey, Kathryn
Perez-Callejo, David
Lundberg, Linda
Relf, James
de L'Etang, Audrey Filezac
Carlile, David
Clark, Emma
Carlo-Stella, Carmelo
BLOOD, 2021, 138
[23] Pharmacological profile and clinical outcomes of KTE-X19 by prior bruton tyrosine kinase inhibitor exposure or mantle cell lymphoma morphology in patients with relapsed/refractory mantle cell lymphoma in the ZUMA-2 trial
Wang, Michael
Rossi, John M.
Munoz, Javier
Goy, Andre
Locke, Frederick L.
Reagan, Patrick M.
Jacobson, Caron A.
Hill, Brian T.
Holmes, Houston
Jaglowski, Samantha
Peng, Weimin
Zheng, Lianqing
Fang, Xiang
Xue, Allen
Kloos, Ioana
Bot, Adrian
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 43 - 44
[24] Gradual High Dosing of Glofitamab Results in high Response Rates in Patients with relapsed/refractory (R/R) Mantle Cell Lymphoma (MCL), most of whom had failed prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy
Dreyling, M.
Phillips, T.
Dickinson, M.
Morschhauser, F.
Bachy, E.
Crump, M.
Trneny, M.
Bartlett, N.
Zaucha, J.
Humphrey, K.
Perez-Callejo, D.
Lundberg, L.
Relf, J.
Filezac, De L'Etang A.
Carlile, D.
Clark, E.
Carlo-Stella, C.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 150 - 150
[25] KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL): Results of the Phase 2 ZUMA-2 Study
Wang, Michael
Munoz, Javier
Goy, Andre
Locke, Frederick L.
Jacobson, Caron A.
Hill, Brian T.
Timmerman, John M.
Holmes, Houston
Jaglowski, Samantha
Flinn, Ian W.
McSweeney, Peter A.
Miklos, David B.
Pagel, John M.
Kersten, Marie Jose
Peng, Weimin
Zheng, Lianqing
Rossi, John M.
Jain, Rajul K.
Rao, Arati V.
Reagan, Patrick M.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S1 - S1
[26] KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study
Wang, Michael L.
Munoz, Javier
Goy, Andre
Locke, Frederick L.
Jacobson, Caron A.
Hill, Brian T.
Timmerman, John M.
Holmes, Houston
Jaglowski, Samantha
Flinn, Ian W.
McSweeney, Peter A.
Miklos, David B.
Pagel, John M.
Kersten, Marie Jose
Peng, Weimin
Zheng, Lianqing
Rossi, John M.
Jain, Rajul K.
Rao, Arati V.
Reagan, Patrick M.
BLOOD, 2019, 134
[27] KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL): Results from Phase 2 of ZUMA-2
Wang, Michael
Munoz, Javier
Goy, Andre
Locke, Frederick L.
Jacobson, Caron A.
Hill, Brian T.
Timmerman, John M.
Holmes, Houston
Jaglowski, Samantha
Flinn, Ian W.
McSweeney, Peter A.
Miklos, David B.
Pagel, John M.
Kersten, Marie Jose
Peng, Weimin
Zheng, Lianqing
Rossi, John M.
Jain, Rajul K.
Rao, Arati V.
Reagan, Patrick M.
MOLECULAR THERAPY, 2020, 28 (04) : 573 - 573
[28] Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR® Registry
Wudhikarn, Kitsada
Bezerra, Evandro
Yang, Yang
Perales, Miguel-Angel
Jain, Nitin
Gergis, Usama
Aribi, Ahmed
Hill, Laquisa
Leonard, Jessica T.
Lutfi, Forat
Kim, Soyoung
Bye, Matthew
Hu, Zhen-Huan
Wang, Hai-Lin
Luo, Zhong-Cheng
Siddiqi, Rubina
Khalid, Rita Damico
Speiser, Jessica
Pasquini, Marcelo C.
Kebriaei, Partow
Muffly, Lori
BLOOD, 2024, 144 : 5092 - 5093
[29] Lisocabtagene maraleucel (liso-cel) in patients (pt) with R/R mantle cell lymphoma (MCL): Subgroup analyses by number of prior systemic lines of therapy (LOT) and by response to prior Bruton tyrosine kinase inhibitor (BTKi) from the TRANSCEND NHL 001 MCL cohort (TRANSCEND-MCL)
Palomba, Maria Lia
Siddiqi, Tanya
Gordon, Leo I.
Kamdar, Manali Kirtikumar
Lunning, Matthew Alexander
Hirayama, Alexandre V.
Abramson, Jeremy S.
Arnason, Jon
Ghosh, Nilanjan
Mehta, Amitkumar
Andreadis, Charalambos
Solomon, Scott R.
Kostic, Ana
Singh, Ashvin
Espinola, Ricardo
Bhatnagar, Rashmi
Raviele, Anthony
Wang, Michael
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[30] Toxicity Profile of Brexucabtagene Autoleucel (brexu-cel; CD19-directed CAR T-cell therapy) in Adult Patients (pts) with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from a Multicenter Real-World Outcomes Study
Kopmar, Noam E.
Gooley, Ted
Roloff, Gregory W.
Aldoss, Ibrahim
Lin, Chenyu
Dekker, Simone E.
Gupta, Vishal K.
Jeyakumar, Nikeshan
O'connor, Timothy
Dykes, Kaitlyn C.
Ahmed, Mohamed
Zambrano, Hector
Bradshaw, Danielle
Mercadal, Santiago
Schwartz, Marc
Tracy, Sean
Dholaria, Bhagirathbhai
Kubiak, Michal
Mukherjee, Akash
Majhail, Navneet
Battiwalla, Minoo
Mountjoy, Luke
Malik, Shabaz
Shaughnessy, Paul
Mathews, John
Logan, Aaron C.
Ladha, Abdullah
Yaghmour, George
Advani, Anjali S.
Stefan, Maryann
Guzowski, Caitlin
Hoeg, Rasmus T.
Hilal, Talal
Moore, Jozal
O'Dwyer, Kristen M.
Tsai, Stephanie B.
Sasine, Joshua
Solh, Melhem M.
Lee, Catherine J.
Kota, Vamsi K.
Koura, Divya
Veeraputhiran, Muthu
Blunk, Betsy
Leonard, Jessica T.
Oliai, Caspian H.
Bachanova, Veronika
Stock, Wendy
Galal, Ahmed
Pullarkat, Vinod
Shah, Bijal D.
BLOOD, 2023, 142

← 1 2 3 4 →